S
Suman Chatterjee
Researcher at University of Pittsburgh
Publications - 18
Citations - 689
Suman Chatterjee is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Cancer & Cancer research. The author has an hindex of 7, co-authored 12 publications receiving 521 citations. Previous affiliations of Suman Chatterjee include West Virginia University & Duquesne University.
Papers
More filters
Journal ArticleDOI
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
TL;DR: The roles of some of the important HSPs in cancer are reviewed, and how targeting them could be efficacious, especially when traditional cancer therapies fail are reviewed.
Journal ArticleDOI
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Zachary A. Yochum,Jessica Cades,Hailun Wang,Suman Chatterjee,Brian W. Simons,James P. O’Brien,Susheel K. Khetarpal,Ghali Lemtiri-Chlieh,Kayla V. Myers,Eric H.-B. Huang,Charles M. Rudin,Phuoc T. Tran,Timothy F. Burns +12 more
TL;DR: TWIST1 is established as a driver of resistance to EGFR TKIs and rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance toEGFR TkIs is provided.
Journal Article
HSP90 inhibitors in lung cancer: promise still unfulfilled.
TL;DR: This review discusses the development and the preclinical and clinical profiles of some of the HSP90 inhibitors that may help to improve the targeted treatment of NSCLC.
Journal ArticleDOI
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Zachary A. Yochum,Jessica Cades,Lucia Mazzacurati,Neil M. Neumann,Susheel K. Khetarpal,Suman Chatterjee,Hailun Wang,Myriam A. Attar,Eric H.-B. Huang,Sarah N. Chatley,Katriana Nugent,Ashwin Somasundaram,Johnathan A. Engh,Andrew J. Ewald,Yoon Jae Cho,Charles M. Rudin,Phuoc T. Tran,Timothy F. Burns +17 more
TL;DR: Harmine is identified as a first-in-class TWIST1 inhibitor with marked anti-tumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLCs.
Journal ArticleDOI
Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
TL;DR: A way forward is offered through the rational design of Hsp90 inhibitor combinations that may prevent and/or overcome resistance to HSp90 inhibitors, providing an effective therapeutic strategy for KRAS-mutant NSCLC.